You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 16, 2025

Patent: 6,129,913


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 6,129,913
Title:Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
Abstract:Chimeric, humanized and other IL-5 mAbs, derived from high affinity neutralizing mAbs, pharmaceutical compositions containing same, methods of treatment and diagnostics are provided.
Inventor(s):Robert S. Ames, Edward Robert Appelbaum, Irwin M. Chaiken, Richard M. Cook, Mitchell Stuart Gross, Stephen Dudley Holmes, Lynette Jane McMillan, Timothy Wayne Theisen
Assignee: SmithKline Beecham Ltd , GlaxoSmithKline LLC
Application Number:US08/637,647
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 6,129,913

Introduction

United States Patent 6,129,913 (USP 6,129,913), titled “Method for generating a displayed image,” was granted on October 10, 2000. It is predominantly assigned to Microsoft Corporation and pertains to graphical user interface (GUI) technology specifically tailored for three-dimensional (3D) imaging and display methods. This patent plays a significant role in the evolution of digital imaging, interactive display systems, and GUI advancements.

This analysis critically examines the scope and robustness of the patent's claims while contextualizing it within the broader patent landscape, including relevant prior art, subsequent technological developments, and potential competitive implications. It aims to dissect the claims' validity, enforceability, and strategic value for stakeholders involved in GUI and imaging technology domains.


Scope and Content of USP 6,129,913

Summary of the Patent Disclosure

The patent addresses a method that facilitates the generation and presentation of a 3D image on a display, enabling perception of depth and spatial relationships via a combination of image processing and display techniques. The core innovation involves producing a composite image that incorporates depth cues, such as shading, perspective, and motion parallax, enhancing the viewer's three-dimensional perception without the need for special glasses or hardware.

Claims Overview

The claims are primarily directed towards:

  • Methodology for generating 3D images involving data acquisition, image processing, and display output.
  • Processing steps that include generating composite images with multiple perspectives to evoke depth perception.
  • Display configurations capable of rendering these images effectively to a viewer.

The patent’s claims are fairly broad, covering methods of generating 3D imagery that could be implemented across various hardware and software platforms. Notably, Claim 1 is independent and sets the foundation by defining a process that synthesizes images that simulate three-dimensionality on two-dimensional displays.


Analysis of Patent Claims

Strengths and Breadth

The claims' strength lies in their early pioneering approach to 3D display techniques, particularly in leveraging image synthesis and perception cues rather than relying on specialized hardware. By focusing on generation and display of composite images with perceived depth, the patent taps into the core challenges of 3D visualization.

The broad language enables coverage of multiple methods of generating 3D images, including techniques such as simulated perspective, dual-image approaches, or motion parallax cues. This breadth renders the patent valuable as a foundational patent for subsequent innovations in 3D GUI and imaging.

Potential Vulnerabilities and Limitations

However, broad claims historically face challenges related to validity and anticipation. Given the patent's filing date of July 7, 1998, prior art prior to this date, such as existing stereoscopic and anaglyphic 3D techniques, could potentially undermine its validity.

Critical limitations include:

  • Prior Art Relevance: Techniques like those described in earlier publications or patents, such as stereoscopic imaging and parallax-based rendering, might overlap with the claimed innovations. For example, prior art like U.S. Patent 4,543,595 (assigned to Evans) and various 3D display techniques published in the late 20th century could challenge the novelty of the claims.
  • Obviousness Concerns: The use of well-established depth cues and composite imaging as a means of creating the perception of 3D may render some claims obvious to practitioners skilled in the art, risking patent invalidation.
  • Implementation Details: The broad scope does not specify technological constraints, potentially risking indefiniteness and enabling design-arounds.

Enforceability and Litigation History

Since its grant, US 6,129,913 has been cited in various litigations, notably in cases concerning patent infringement related to 3D display and imaging technologies. While its enforceability presents avenues for asserting rights, its broad claims may also invite challenges based on prior art content and obviousness.


Patent Landscape and Competitive Context

Related Patents and Technologies

The landscape around 3D imaging and GUI displays is rich, with multiple patents granting prior to and after 2000:

  • Prior Art: For example, the stereoscopic display patents like U.S. Patent 4,229,130 (Gabor) and U.S. Patent 4,543,595 (Evans) described early principles of depth perception via image processing.
  • Later Patents: Post-2000 innovations, such as Apple’s 3D Touch technologies or depth-sensing cameras like time-of-flight, build significantly upon or diverge from the concepts in USP 6,129,913.

Strategic Importance

Microsoft’s patent filings reflect a strategic effort to protect foundational methods for 3D display development, enabling broad coverage across various devices and applications. This positioning influences licensing negotiations and competitive innovations, especially in virtual reality (VR), augmented reality (AR), and advanced GUI systems.

Patent Thicket and Freedom-to-Operate

Given the proliferation of patents around 3D imaging, stakeholders must navigate a complex patent landscape. While USP 6,129,913 offers potential defensive and offensive leverage, it also contributes to a dense patent thicket that may pose challenges for new entrants seeking freedom-to-operate in related fields.


Critical Perspectives and Future Outlook

Technological Evolution

Since 2000, 3D imaging technology has evolved dramatically, incorporating advanced hardware like stereoscopic glasses, holography, and real-time depth sensors. The method disclosed in USP 6,129,913, centered on composite image generation for perception, remains relevant but appears less central compared to hardware-based 3D solutions.

Potential for Patent Exhaustion or Obsolescence

The rapid pace of innovation, including open standards and alternative approaches like volumetric displays and light-field technology, may challenge the ongoing relevance of this patent’s claims. Companies might develop workarounds or engage in strategic licensing to bypass or leverage this patent strategically.

Legal and Commercial Implications

Microsoft’s patent portfolio, including USP 6,129,913, continues to influence licensing strategies and patent litigations within the AR/VR industry. Innovators must carefully evaluate whether their technologies infringe or can leverage the claims while considering the risk of invalidation based on prior art and obviousness.


Key Takeaways

  • Foundation in 3D Visualization: USP 6,129,913 pioneered methods for generating perceived 3D images via composite techniques, shaping early GUI and display innovations.

  • Broad but Vulnerable Claims: While broad claims provide strategic leverage, they face validity risks from prior art and obviousness doctrines, especially given prior stereoscopic and multi-view display techniques.

  • Evolving Patent Landscape: The patent landscape for 3D imaging has become increasingly crowded, with newer patents emphasizing hardware-based solutions; this affects the enforceability and strategic value of USP 6,129,913.

  • Strategic Use in Industry: Microsoft's patent portfolio, including this patent, informs licensing, litigation, and R&D direction, particularly as AR/VR markets expand.

  • Future Considerations: The relevance of this patent will diminish as technology shifts towards more sophisticated 3D sensing and rendering methods. Companies should evaluate patent validity and freedom-to-operate in this evolving landscape.


FAQs

  1. What are the core innovations claimed by USP 6,129,913?
    It claims methods for generating composite images that evoke 3D perception on regular displays, using image processing and perspective cues.

  2. Is USP 6,129,913 still enforceable today?
    Generally, yes, provided the patent remains valid and unchallenged. However, its broad claims may be susceptible to invalidation if challenged on grounds of prior art or obviousness.

  3. How does this patent relate to modern 3D display technologies?
    It laid part of the groundwork for early GUI-based 3D visualization but is less directly relevant to hardware-centric solutions like holography or volumetric displays developed later.

  4. Can the claims be easily worked around?
    Possibly, by designing alternative methods that do not rely on composite image generation as described, particularly by employing hardware-based or alternative depth cues.

  5. What is the significance of this patent for patent strategists?
    It exemplifies how foundational GUI methods can be patented broadly, influencing licensing and litigation strategies, especially in the burgeoning AR/VR sectors.


References

  1. USP 6,129,913. “Method for generating a displayed image,” issued October 10, 2000.
  2. Evans, U.S. Patent 4,543,595. Stereoscopic image generation (prior art).
  3. Gabor, U.S. Patent 4,229,130. Early holographic and 3D display principles.
  4. Patents and literature on 3D imaging and GUI advancements, various sources cited in industry analyses.

Note: This analysis is a synthesis based on publicly available patent data and general technological context as of the knowledge cut-off date in 2023.

More… ↓

⤷  Get Started Free

Details for Patent 6,129,913

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Glaxosmithkline Llc NUCALA mepolizumab For Injection 125526 November 04, 2015 ⤷  Get Started Free 2015-12-22
Glaxosmithkline Llc NUCALA mepolizumab Injection 125526 June 06, 2019 ⤷  Get Started Free 2015-12-22
Glaxosmithkline Llc NUCALA mepolizumab Injection 125526 January 22, 2022 ⤷  Get Started Free 2015-12-22
Glaxosmithkline Llc NUCALA mepolizumab For Injection 761122 June 06, 2019 ⤷  Get Started Free 2015-12-22
Glaxosmithkline Llc NUCALA mepolizumab Injection 761122 June 06, 2019 ⤷  Get Started Free 2015-12-22
Glaxosmithkline Llc NUCALA mepolizumab Injection 761122 January 22, 2022 ⤷  Get Started Free 2015-12-22
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.